SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| Sanchez Ramiro | Director | 2026-10-23 | Open-market buy | 3600 | $98K |
| MARAGANORE JOHN | Director | 2026-10-22 | Open-market buy | 8239 | $217K |
| MARAGANORE JOHN | Director | 2026-10-22 | Open-market buy | 1172 | $32K |
| PAUL STEVEN M | Director | 2026-10-22 | Open-market buy | 35714 | $974K |
| Silva Paul M | Director | 2026-10-22 | Open-market buy | 3680 | $100K |
| Young Wendy B. | Director | 2026-10-22 | Open-market buy | 3789 | $100K |
| Ceesay Abraham | Chief Executive Officer, Director | 2026-10-21 | Open-market sell 10b5-1 | 2210 | $64K |
| Ignelzi Troy A. | Chief Financial Officer | 2026-10-21 | Open-market buy | 5500 | $144K |
| Ceesay Abraham | Chief Executive Officer, Director | 2026-10-07 | Open-market sell 10b5-1 | 1147 | $35K |
| Ceesay Abraham | Chief Executive Officer, Director | 2026-10-06 | Open-market sell 10b5-1 | 3375 | $108K |
| Gault Cheryl | Chief Operating Officer | 2026-09-30 | Open-market sell 10b5-1 | 7925 | $262K |
| Gault Cheryl | Chief Operating Officer | 2026-09-30 | Open-market sell 10b5-1 | 2075 | $70K |
| Ceesay Abraham | Chief Executive Officer, Director | 2026-09-23 | Open-market sell 10b5-1 | 1952 | $76K |
| Ceesay Abraham | Chief Executive Officer, Director | 2026-09-23 | Open-market sell 10b5-1 | 215 | $9K |
| Ceesay Abraham | Chief Executive Officer, Director | 2026-09-23 | Open-market sell 10b5-1 | 43 | $2K |
| Ceesay Abraham | Chief Executive Officer, Director | 2026-09-08 | Open-market sell 10b5-1 | 7141 | $325K |
| Ceesay Abraham | Chief Executive Officer, Director | 2026-09-08 | Open-market sell 10b5-1 | 1069 | $49K |
| Ceesay Abraham | Chief Executive Officer, Director | 2026-08-25 | Open-market sell 10b5-1 | 18921 | $938K |
| Yeleswaram Krishnaswamy | Chief Development Officer | 2026-08-25 | Open-market sell 10b5-1 | 20799 | $1.0M |
| Yeleswaram Krishnaswamy | Chief Development Officer | 2026-08-25 | Open-market sell 10b5-1 | 16201 | $827K |
Rapport announced positive topline results from a Phase 2 trial of RAP-219 for bipolar mania, meeting primary and secondary endpoints with statistically significant improvements in YMRS and CGI-BP scores and a favorable safety profile. This clinical development milestone establishes proof-of-concept for the company's lead candidate and supports progression to Phase 3 trials expected in H2 2027.
View raw filing on EDGAR →This is a quarterly earnings release for Q2 2026 filed under Item 2.02. The disclosure includes financial results (net loss of $56.6M, R&D expenses of $51.4M, cash position of $436.1M), condensed consolidated financial statements, and business highlights regarding clinical trial progress for RAP-219 and pipeline advancement. The press release is furnished as Exhibit 99.1, which is the standard format for earnings disclosures under Item 2.02.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Rapport Therapeutics' 2026 Annual Meeting of Stockholders held on June 10, 2026. The filing reports voting outcomes for two proposals: (i) election of three Class II directors (James Healy, Robert J. Perez, and Raymond Sanchez) and (ii) ratification of PwC as the independent auditor. The detailed vote tallies (For/Withheld/Broker Non-Votes for directors; For/Against/Abstain for auditor ratification) are the core content of Item 5.07, making this a textbook shareholder_vote_results event that is material to investors assessing board composition and audit oversight.
View raw filing on EDGAR →